GARDP wants five AMR breakers by 2025GARDP has called up the global community to develop and deliver five new treatments that break antimicrobial resistance (AMR) by 2025. more ➔
Sanifit raise €72.2m to push SNF472 deve...Sanifit has bagged €72.2m in Spain’s largest private biotech fundraise. more ➔
Genfit in $228m deal with Terns Pharmaceut...Genfit SA has licenced the Greater China commercialisation rights for its NASH drug elafibranor to Terns Pharmaceuticals Inc.   … more ➔
Vesalius Biocapital III Fund closes at €...Life sciences venture capitalist Vesalius Biocapital III has announced the final close of the VBC III fund at €120m. more ➔
Erytech Pharma SA bags US$57m from SQZ Bio...Erytech Pharma has inked a deal with SQZ Biotechnologies Inc. to develop new immune modulating therapies. more ➔
Sanofi/Regeneron’s IL-33 blocker mee...Sanofis and Regenerons IL-33 blocker REGN3500 met primary Phase II endpoint in asthma patients. more ➔
Karo Pharma acquires Trimb ABKaro Pharma AB announced it will acquire Trimb Holding AB for MSEK3,400 (€319.6m) and intends to carry out a Rights Issue of about MSEK 1,500 (€141m). more ➔
UK biotech to make proteins from carbon di...Deep Branch Biotechnology Ltd. from Nottingham has started a feasibility study with the British energy supplier Drax Group. The technology to be analysed converts carbon dioxide emitted by power … more ➔
GM proponents grill German governmentGerman GM proponents have taken action against discrimination of food products generated by gene editing. more ➔
Human cell chip predicts chemotherapy effe... Roche and US company Hesperos Inc have used human cancer and organ cells, placed in a 5-chamber microfluidic chip, to predict chemotherapy safety and efficacy preclinically. more ➔
